Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17315470 | 0.86 | F2 (0.46) | CA2 | |
| SCHEMBL13211316 | 0.85 | GPR119 (0.42) | CA2KAT6AGPR119CCR2KCNH2 | |
| SCHEMBL27690017 | 0.84 | CCR2 (0.38) | GPR119CCR2KCNH2CHRM4 | |
| SCHEMBL22792699 | 0.84 | CA2 (0.53) | CA2KAT6ACNR1CNR2 | |
| SCHEMBL16352070 | 0.82 | GPR119 (0.40) | GPR119CCR2KCNH2MDM2CHRM4 | |
| SCHEMBL30193194 | 0.80 | PSIP1 (0.40) | CA2GPR119CCR2KCNH2CHRM4 | |
| SCHEMBL1940032 | 0.80 | CYP4F2 (0.44) | CA2GPR119CCR2KCNH2CHRM4 | |
| SCHEMBL30457289 | 0.80 | CCR2 (0.40) | GPR119CCR2KCNH2CHRM4 | |
| SCHEMBL5273904 | 0.80 | PSIP1 (0.40) | CA2GPR119CCR2KCNH2CHRM4 | |
| SCHEMBL1940002 | 0.80 | CCR2 (0.40) | GPR119CCR2KCNH2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197977-A9 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2017-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197977-A9 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, CHRNB2 | CA2 4078/4885KAT6A 1724/4885GPR119 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.